|
Last
updated:
June 20, 2004
LPV/RTV/Atorvastatin
CONFERENCE POSTER
Pharmacokinetic
Interactions between Lopinavir/Ritonavir (ABT-378/r) and
Other Non-HIV Drugs.
Bertz
R, Hsu A, Lam W, et al.
Poster
Abstract
LPV/RTV/Ethinyl Estradiol
CONFERENCE POSTER
Pharmacokinetic
Interactions between Lopinavir/Ritonavir (ABT-378/r) and
Other Non-HIV Drugs.
Bertz
R, Hsu A, Lam W, et al
Poster
Abstract
LPV/RTV
Ketoconazole
CONFERENCE POSTER
Pharmacokinetic
Interactions between Lopinavir/Ritonavir (ABT-378/r) and
Other Non-HIV Drugs.
Bertz
R, Hsu A, Lam W, et al.
Poster
Abstract
LPV/RTV
Methadone
CONFERENCE POSTER
Pharmacokinetic
Interactions between Lopinavir/Ritonavir (ABT-378/r) and
Other Non-HIV Drugs.
Bertz
R, Hsu A, Lam W, et al.
Poster
Abstract
LPV/RTV/NFV
LPV/RTV/NVP
CONFERENCE POSTER
Assessment of the
Pharmacokinetic Interactions between Lopinavir/Ritonavir
(ABT-378/r)
(Lopinavir/Ritonavir) and Nevirapine (NVP) in HIV-Infected Pediatric
Subjects.
Bernstein B, Kempf D,
Moseley J, et al.
Poster
Abstract
LPV/RTV/Norethindrone
CONFERENCE POSTER
Pharmacokinetic
Interactions between Lopinavir/Ritonavir (ABT-378/r) and
Other Non-HIV Drugs.
Bertz
R, Hsu A, Lam W, et al.
Poster Abstract
LPV/RTV/Pravastatin
CONFERENCE POSTER
Pharmacokinetic
Interactions between Lopinavir/Ritonavir (ABT-378/r) and
Other Non-HIV Drugs.
Bertz
R, Hsu A, Lam W, et al.
Poster Abstract
LPV/RTV/Rifabutin
CONFERENCE POSTER
Pharmacokinetic
Interactions between Lopinavir/Ritonavir (ABT-378/r) and
Other Non-HIV Drugs.
Bertz
R, Hsu A, Lam W,et al.
Poster Abstract
LPV/RTV/
Rifampin
CONFERENCE POSTER
Pharmacokinetic
Interactions between Lopinavir/Ritonavir (ABT-378/r) and
Other Non-HIV Drugs.
Bertz R, Hsu A, Lam W, et al.
Poster Abstract
CONFERENCE POSTER
Lack of Resistance to ABT-Ritonavir
(ABT-378/r) after 24 Weeks of Therapy in
Antiretroviral Naïve Subjects .
Bernstein B, Kempf D, Moseley J, et al.
Poster Abstract
Examination of the Genetic Barrier to In Vivo Resistance to
ABT-378/Ritonavir
(ABT-378/r) in Protease Inhibitor Experiences Patients Using the ABT-378
Mutation
Score.
Brun
S, Kempf D Bernstein B, et al.
Abstract
CONFERENCE POSTER
Interpretation of Genotypic
Resistance to ABT-378/Ritonavir (ABT-378/r) in
Protease Inhibitor Experienced
Patients Using the ABT-378 Mutation
Score
Kempf D, Isaacson J, King M,
et al
Poster Abstract
Interpretation of Phenotypic Resistance to
ABT-378/Ritonavir (ABT-378/r) in
Protease Inhibitor Experienced Patients
Kempf D,
Isaacson J, King M, et al
Abstract
|
Pediatric Treatment
Indications |
| |
LPV/RTV/D4T/3TC
in ARV-naïve patients
LPV/RTV/D4T/3TC in ARV-naïve patients (Study M98-940)
Efficacy
| |
CONFERENCE POSTER
ABT-378/Ritonavir
(ABT-378/r) in HIV-Infected Children at 48 Weeks
(Study M98-940).
Cahn P, Renz C, Deetz C, et al.
Poster Abstract |
|
LPV/RTV/NFV
Dosing Study
| |
CONFERENCE POSTER
Assessment of the
Pharmacokinetic Interactions between Lopinavir/Ritonavir
ABT-378/r)
(Lopinavir/Ritonavir) and Nevirapine (NVP) in HIV-Infected Pediatric
Subjects.
Bernstein B, Kempf D, Moseley J, et al.
Poster Abstract
|
|
|
Adolescent/Adult Treatment
Indications |
| |
LPV/RTV/D4T/3TC
in ARV-naïve
patients (Study M97-720)
Efficacy
| |
CONFERENCE POSTER
ABT-378/Ritonavir (ABT-378/r) in Antiretroviral-Naïve HIV+ Patients: Follow
Up
Beyond Two Years and Viral Load Suppression Below 3 Copies/mL
Stryker
R, Brun S, King M ,et al.
Poster Abstract |
|
LPV/RTV/EFV/Multiple
PIs
in ARV-experienced patient
Efficacy
| |
ABT-378/Ritonavir (ABT-378/r) and Efavirenz: One Year
Safety/Efficacy Evaluation
in Multiple PI Experienced Patients (M98-957 Study).
Rockstroh J, Brun S, Sylte J, et al.
Abstract
CONFERENCE POSTER
Kaletra (ABT-378/ritonavir) and
Efavirenz: 48-Week Safety/Efficacy Evaluation in
Multiple PI-Experienced
Patients (M98-957 Study).
Rockstroh
J, Brun S, Bertz R, et al.
Poster
|
|
LPV/RTV/NVP/2NRTIs
Efficacy
| |
CONFERENCE POSTER
Durable Suppression of HIV+
RNA after Two Years of Therapy with
ABT-378/Ritonavir (ABT-378/r) Treatment
in Single Protease Inhibitor
Experienced Patients (M97-765 Study).
Feinberg J, Brun S, Marsh T, et al.
Poster Abstract |
|
LPV/RTV/D4T/3TC
vs NFV/D4T/3TC
(Study M98-863)
Treatment of HIV Infection/Disease
Efficacy
| |
ABT-378/Ritonavir
(ABT-378/r) vs. Nelfinavir in Antiretroviral-Naïve
Subjects: Week 48
Comparison in a Phase III Blinded
Randomized
Clinical Trial (Study
M98-863).
Johnson
M, Beall G, Badley A, et al
Abstract |
|
Resistance
| |
CONFERENCE POSTER
Lack of Resistance to ABT-378/Ritonavir (ABT-378/r) after 24 Weeks of
Therapy in
Antiretroviral Naïve Subjects
Bernstein B, Kempf D, Moseley J,
et al.
Poster
Abstract
|
|
Treatment of HIV/HBV or HIV/HCV Coinfection
Efficacy
| |
CONFERENCE POSTER
Treatment
of HIV+ Subjects Co-infected with Hepatitis B or C: Safety and
Efficacy
Comparison of ABT-378/Ritonavir (ABT-378/r) vs. Nelfinavir from a
Phase III
Randomized Clinical Trial (Study M98-863).
Arribas
J, Barros C, Gonzalez-Lahoz J,
et al.
Poster Abstract |
|
|
KLS
Main Page